Arbutus Biopharma Corp Foreign Currency Transaction Gain (Loss), Unrealized
Arbutus Biopharma Corp (ABUS) reported Foreign Currency Transaction Gain (Loss), Unrealized of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2022-08-04
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for the quarter ending 2022-06-30 was $0.00.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for the quarter ending 2022-03-31 was $0.00.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for the quarter ending 2021-12-31 was $5.00K, a 95.54% decline year-over-year.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for the quarter ending 2021-09-30 was $44.00K.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for fiscal 2021 was $5.00K, a 91.07% decline from fiscal 2020.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for fiscal 2020 was $56.00K, a 17.65% decline from fiscal 2019.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for fiscal 2019 was $68.00K.
- Arbutus Biopharma Corp foreign currency transaction gain (loss), unrealized for fiscal 2018 was -$1.00M, a 142.25% decline from fiscal 2017.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 3 month as first filed | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $5.00K derived: sum of 3 quarters · filed 2022-08-04 | $49.00K derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $5.00K derived: sum of 2 quarters · filed 2022-05-05 | $49.00K derived: sum of 3 quarters · filed 2022-05-05 | $49.00K derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $49.00K derived: sum of 2 quarters · filed 2022-03-03 | $49.00K derived: sum of 3 quarters · filed 2022-08-04 | $5.00K 10-K · filed 2022-03-03 | ||
| 2021-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $44.00K derived: sum of 2 quarters · filed 2022-08-04 | $0.00 10-Q · filed 2021-11-04 | $112.00K derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$44.00K 10-Q · filed 2022-08-04 | $68.00K derived: sum of 3 quarters · filed 2022-08-04 | $68.00K derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | -$44.00K 10-Q · filed 2022-05-05 | $68.00K derived: sum of 2 quarters · filed 2022-05-05 | $68.00K derived: sum of 3 quarters · filed 2022-05-05 | $22.00K derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $112.00K derived: sum of 2 quarters · filed 2022-03-03 | $66.00K derived: sum of 3 quarters · filed 2022-03-03 | $56.00K 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$46.00K derived: sum of 2 quarters · filed 2021-11-04 | -$56.00K 10-Q · filed 2021-11-04 | -$59.00K derived: sum of 4 quarters · filed 2021-11-04 | ||
| 2020-06-30 | -$46.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$56.00K 10-Q · filed 2021-08-05 | -$59.00K derived: sum of 3 quarters · filed 2021-08-05 | -$83.00K derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | -$10.00K 10-Q · filed 2021-05-05 | -$13.00K derived: sum of 2 quarters · filed 2021-05-05 | -$37.00K derived: sum of 3 quarters · filed 2021-05-05 | $20.00K derived: sum of 4 quarters · filed 2021-05-05 | ||
| 2019-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$27.00K derived: sum of 2 quarters · filed 2021-03-04 | $30.00K derived: sum of 3 quarters · filed 2021-03-04 | $68.00K 10-K · filed 2021-03-04 | ||
| 2019-09-30 | -$24.00K 10-Q · filed 2019-11-06 | $33.00K derived: sum of 2 quarters · filed 2019-11-06 | $71.00K 10-Q · filed 2020-11-05 | -$137.00K derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2019-06-30 | $57.00K 10-Q · filed 2019-08-05 | $95.00K 10-Q · filed 2020-08-07 | -$113.00K derived: sum of 3 quarters · filed 2020-05-11 | $18.00K derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2019-03-31 | $38.00K 10-Q · filed 2020-05-11 | -$170.00K derived: sum of 2 quarters · filed 2020-05-11 | -$39.00K derived: sum of 3 quarters · filed 2020-05-11 | -$400.00K derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2018-12-31 | -$208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$77.00K derived: sum of 2 quarters · filed 2020-03-05 | -$438.00K derived: sum of 3 quarters · filed 2020-03-05 | -$1.00M 10-K · filed 2020-03-05 | ||
| 2018-09-30 | $131.00K 10-Q · filed 2019-11-06 | -$230.00K derived: sum of 2 quarters · filed 2019-11-06 | -$795.00K 10-Q · filed 2019-11-06 | -$999.00K derived: sum of 4 quarters · filed 2019-11-06 | ||
| 2018-06-30 | -$361.00K 10-Q · filed 2019-08-05 | -$926.00K 10-Q · filed 2019-08-05 | -$1.13M derived: sum of 3 quarters · filed 2019-08-05 | $198.00K derived: sum of 4 quarters · filed 2019-08-05 | ||
| 2018-03-31 | -$565.00K 10-Q · filed 2019-05-06 | -$769.00K derived: sum of 2 quarters · filed 2019-05-06 | $559.00K derived: sum of 3 quarters · filed 2019-05-06 | $1.38M derived: sum of 4 quarters · filed 2019-05-06 | ||
| 2017-12-31 | -$204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.12M derived: sum of 2 quarters · filed 2019-03-07 | $1.95M derived: sum of 3 quarters · filed 2019-03-07 | $2.37M 10-K · filed 2019-03-07 | ||
| 2017-09-30 | $1.33M 10-Q · filed 2018-11-07 | $2.15M derived: sum of 2 quarters · filed 2018-11-07 | $2.58M 10-Q · filed 2018-11-07 | $1.45M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | $824.00K 10-Q · filed 2018-08-03 | $1.25M 10-Q · filed 2018-08-03 | $122.00K derived: sum of 3 quarters · filed 2018-08-03 | -$704.00K derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | $425.00K 10-Q · filed 2018-05-04 | -$702.00K derived: sum of 2 quarters · filed 2018-05-04 | -$1.53M derived: sum of 3 quarters · filed 2018-05-04 | -$1.58M derived: sum of 4 quarters · filed 2018-05-04 | ||
| 2016-12-31 | -$1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$1.95M derived: sum of 2 quarters · filed 2018-03-16 | -$2.00M derived: sum of 3 quarters · filed 2018-03-16 | $1.00M 10-K · filed 2018-03-16 | ||
| 2016-09-30 | -$826.00K 10-Q · filed 2017-11-02 | -$877.00K derived: sum of 2 quarters · filed 2017-11-02 | $2.13M 10-Q · filed 2017-11-02 | $7.89M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-06-30 | -$51.00K 10-Q · filed 2017-08-03 | $2.96M 10-Q · filed 2017-08-03 | $8.71M derived: sum of 3 quarters · filed 2018-03-16 | $20.50M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-03-31 | $3.01M 10-Q · filed 2017-05-04 | $8.76M derived: sum of 2 quarters · filed 2018-03-16 | $20.55M derived: sum of 3 quarters · filed 2018-03-16 | $17.91M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2015-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $17.55M derived: sum of 2 quarters · filed 2018-03-16 | $14.91M derived: sum of 3 quarters · filed 2018-03-16 | $21.97M 10-K · filed 2018-03-16 | ||
| 2015-09-30 | $11.79M 10-Q · filed 2016-11-03 | $9.15M derived: sum of 2 quarters · filed 2016-11-03 | $16.21M 10-Q · filed 2016-11-03 | $18.51M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-06-30 | -$2.64M 10-Q · filed 2016-08-04 | $4.42M 10-Q · filed 2016-08-04 | $6.72M derived: sum of 3 quarters · filed 2017-03-22 | $9.97M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-03-31 | $7.06M 10-Q · filed 2016-05-04 | $9.36M derived: sum of 2 quarters · filed 2017-03-22 | $12.61M derived: sum of 3 quarters · filed 2017-03-22 | $11.22M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2014-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $5.55M derived: sum of 2 quarters · filed 2017-03-22 | $4.16M derived: sum of 3 quarters · filed 2017-03-22 | $4.22M 10-K · filed 2017-03-22 | ||
| 2014-09-30 | $3.25M 10-Q · filed 2015-11-05 | $1.85M derived: sum of 2 quarters · filed 2015-11-05 | $1.91M 10-Q · filed 2015-11-05 | $1.96M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-06-30 | -$1.39M 10-Q · filed 2015-08-07 | -$1.33M 10-Q · filed 2015-08-07 | -$1.29M derived: sum of 3 quarters · filed 2016-03-09 | -$1.30M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-03-31 | $59.00K 10-Q · filed 2014-05-14 | $101.00K derived: sum of 2 quarters · filed 2016-03-09 | $86.00K derived: sum of 3 quarters · filed 2016-03-09 | $71.00K derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2013-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $27.00K derived: sum of 2 quarters · filed 2016-03-09 | $12.00K derived: sum of 3 quarters · filed 2016-03-09 | $18.00K 10-K · filed 2016-03-09 | $18.12K 6-K · filed 2014-03-06 | |
| 2013-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$30.00K derived: sum of 2 quarters · filed 2014-11-07 | -$24.00K 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | -$15.00K 10-Q · filed 2014-11-07 | -$3.00K 10-Q · filed 2014-08-14 | -$9.00K 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | -$6.00K 10-Q · filed 2014-05-14 | |||||
| 2012-12-31 | -$29.29K 10-K · filed 2014-03-28 | |||||
| 2011-12-31 | $20.33K 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |